{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,14]],"date-time":"2025-12-14T15:53:37Z","timestamp":1765727617381,"version":"3.48.0"},"reference-count":27,"publisher":"BMJ","issue":"6","license":[{"start":{"date-parts":[[2025,6,16]],"date-time":"2025-06-16T00:00:00Z","timestamp":1750032000000},"content-version":"unspecified","delay-in-days":15,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Programme Hospitalier de Recherche Clinique National","award":["2016-0491"],"award-info":[{"award-number":["2016-0491"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2025,5,23]]},"published-print":{"date-parts":[[2025,6]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Biological disease modifying antirheumatic drugs (bDMARDs) have a central role in the treatment of rheumatoid arthritis (RA). Tumour necrosis factor inhibitors (TNFis) are commonly used as first-line agents, while non-TNFis (tocilizumab, abatacept and rituximab) have shown to be non-inferior to TNFis in head-to-head trials. In case of TNFi inadequate response, using other mechanisms of action provides a better response than using an alternate TNFi. Which non-TNFi bDMARD administered subcutaneously to allow for ambulatory management to choose in case of first line TNFi inadequate response has not been tested in a randomised clinical trial, while observational data support a potential superiority of tocilizumab over abatacept.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analysis<\/jats:title>\n                    <jats:p>The SUNSTAR (SUbcutaNeouS Tocilizumab vs Abatacept in TNF Alpha inadequate responders for the treatment of Rheumatoid arthritis) study is a 52-week prospective, randomised, multicentre, open-label, superiority phase IV trial comparing subcutaneous tocilizumab with abatacept in a 1:1 ratio. Patients with active RA (Disease Activity Score-erythrocyte sedimentation rate &gt;3.2\u2009and Clinical Disease Activity Index (CDAI) &gt;10) and with inadequate 3-month response to a first or second TNFi are included in 25 centres in France. The primary outcome is the CDAI improvement at week 24. Intention-to-treat analysis will be applied primarily. The secondary outcome is a composite outcome of the percentage of responders defined as a CDAI&lt;10, no use of rescue treatment after week 12 and no experimental treatment change, at weeks 12, 24 and 52.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ethics and dissemination<\/jats:title>\n                    <jats:p>Ethics approval was obtained from the committee for the protection of persons (Comit\u00e9 de protection des personnes Sud M\u00e9diterran\u00e9e I 17.00608.001744). The findings from this study, whether positive or negative, will be published in peer-reviewed journals and will be presented at national and international conferences. The results will inform future recommendations on the management of RA.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT03227419\">NCT03227419<\/jats:ext-link>\n                      and EudraCT2017-000947-41.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2024-098298","type":"journal-article","created":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T06:20:44Z","timestamp":1750141244000},"page":"e098298","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Abatacept versus tocilizumab for the treatment of rheumatoid arthritis in TNF inhibitor inadequate responders: study protocol of the SUNSTAR randomised controlled open-label superiority trial"],"prefix":"10.1136","volume":"15","clinical-trial-number":[{"clinical-trial-number":"nct03227419","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8395-826X","authenticated-orcid":false,"given":"Tristan","family":"Pascart","sequence":"first","affiliation":[{"name":"Department of Rheumatology, Universit\u00e9 Catholique de Lille H\u00f4pital Saint Philibert, Lomme, Nord-Pas-de-Calais-Picardie, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruno","family":"Fautrel","sequence":"additional","affiliation":[{"name":"Rheumatology, Piti\u00e9-Salp\u00eatri\u00e8re University Hospital, Paris, \u00cele-de-France, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacques-Eric","family":"Gottenberg","sequence":"additional","affiliation":[{"name":"Rheumatology, Hopitaux universitaires de Strasbourg, Strasbourg, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincent","family":"Ducoulombier","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Universit\u00e9 Catholique de Lille H\u00f4pital Saint Philibert, Lomme, Nord-Pas-de-Calais-Picardie, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christophe","family":"Richez","sequence":"additional","affiliation":[{"name":"Rheumatology, CHU Bordeaux GH Pellegrin, Bordeaux, Nouvelle-Aquitaine, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie-Elise","family":"Truchetet","sequence":"additional","affiliation":[{"name":"Rheumatology, CHU Bordeaux GH Pellegrin, Bordeaux, Nouvelle-Aquitaine, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00e9r\u00f4me","family":"Avouac","sequence":"additional","affiliation":[{"name":"Universit\u00e9 Paris Cit\u00e9 UFR de M\u00e9decine Site Cochin, Paris, \u00cele-de-France, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacques","family":"Morel","sequence":"additional","affiliation":[{"name":"Rheumatology, CHU de Montpellier, Montpellier, Occitanie, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andr\u00e9","family":"Basch","sequence":"additional","affiliation":[{"name":"Rheumatology, Protestant Infirmary of Lyon, Caluire-et-Cuire, Auvergne-Rh\u00f4ne-Alpes, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8852-3687","authenticated-orcid":false,"given":"Gr\u00e9goire","family":"Cormier","sequence":"additional","affiliation":[{"name":"Rheumatology, Centre Hospitalier Departemental Vendee, La Roche-sur-Yon, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"The SUNSTAR Study Group","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"The CRI-IMIDIATE Network","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Houvenagel","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Universit\u00e9 Catholique de Lille H\u00f4pital Saint Philibert, Lomme, Nord-Pas-de-Calais-Picardie, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xavier","family":"Mariette","sequence":"additional","affiliation":[{"name":"Rheumatology, H\u00f4pital Bic\u00eatre, Le Kremlin-Bicetre, \u00cele-de-France, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laur\u00e8ne","family":"Norberciak","sequence":"additional","affiliation":[{"name":"Methodology Unit, Groupement des H\u00f4pitaux de l\u2019Institut Catholique de Lille, Lomme, France"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2025,6,17]]},"reference":[{"key":"2025121407493758000_15.6.e098298.1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)01525-8"},{"key":"2025121407493758000_15.6.e098298.2","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-223356"},{"key":"2025121407493758000_15.6.e098298.3","doi-asserted-by":"crossref","first-page":"105790","DOI":"10.1016\/j.jbspin.2024.105790","article-title":"2024 update of the recommendations of the French Society of Rheumatology for the diagnosis and management of patients with rheumatoid arthritis","volume":"91","author":"Fautrel","year":"2024","journal-title":"Joint Bone Spine"},{"key":"2025121407493758000_15.6.e098298.4","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204573"},{"key":"2025121407493758000_15.6.e098298.5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2014.05.002"},{"key":"2025121407493758000_15.6.e098298.6","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)60250-0"},{"key":"2025121407493758000_15.6.e098298.7","doi-asserted-by":"publisher","DOI":"10.1002\/art.37711"},{"key":"2025121407493758000_15.6.e098298.8","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)00380-9"},{"key":"2025121407493758000_15.6.e098298.9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2008250"},{"key":"2025121407493758000_15.6.e098298.10","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2023-224116"},{"key":"2025121407493758000_15.6.e098298.11","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.13512"},{"key":"2025121407493758000_15.6.e098298.12","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2020-001174","article-title":"Comparative effectiveness of antitumour necrosis factor agents, biologics with an alternative mode of action and tofacitinib in an observational cohort of patients with rheumatoid arthritis in Switzerland","volume":"6","author":"Finckh","year":"2020","journal-title":"RMD Open"},{"key":"2025121407493758000_15.6.e098298.13","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2011-200882"},{"key":"2025121407493758000_15.6.e098298.14","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-203993"},{"key":"2025121407493758000_15.6.e098298.15","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.092932"},{"key":"2025121407493758000_15.6.e098298.16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa050524"},{"key":"2025121407493758000_15.6.e098298.17","doi-asserted-by":"publisher","DOI":"10.1002\/art.22025"},{"key":"2025121407493758000_15.6.e098298.18","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-015-0630-5","article-title":"Cost-effectiveness of abatacept, rituximab, and TNFi treatment after previous failure with TNFi treatment in rheumatoid arthritis: a pragmatic multi-centre randomised trial","volume":"17","author":"Manders","year":"2015","journal-title":"Arthritis Res Ther"},{"key":"2025121407493758000_15.6.e098298.19","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.l67","article-title":"Comparative effectiveness of rituximab, abatacept, and tocilizumab in adults with rheumatoid arthritis and inadequate response to TNF inhibitors: prospective cohort study","volume":"364","author":"Gottenberg","year":"2019","journal-title":"BMJ"},{"key":"2025121407493758000_15.6.e098298.20","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1111\/1756-185X.12822","article-title":"Comparative efficacy and safety of tocilizumab, rituximab, abatacept and tofacitinib in patients with active rheumatoid arthritis that inadequately responds to tumor necrosis factor inhibitors: a Bayesian network meta-analysis of randomized controlled trials","volume":"19","author":"Lee","year":"2016","journal-title":"Int J Rheum Dis"},{"key":"2025121407493758000_15.6.e098298.21","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204417"},{"key":"2025121407493758000_15.6.e098298.22","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.138461"},{"key":"2025121407493758000_15.6.e098298.23","first-page":"S100","article-title":"The Simplified Disease Activity Index (SDAI) and the Clinical Disease Activity Index (CDAI): a review of their usefulness and validity in rheumatoid arthritis","volume":"23","author":"Aletaha","year":"2005","journal-title":"Clin Exp Rheumatol"},{"key":"2025121407493758000_15.6.e098298.24","doi-asserted-by":"publisher","DOI":"10.1002\/art.27740"},{"key":"2025121407493758000_15.6.e098298.25","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1002\/acr.22606","article-title":"Determining the Minimally Important Difference in the Clinical Disease Activity Index for Improvement and Worsening in Early Rheumatoid Arthritis Patients","volume":"67","author":"Curtis","year":"2015","journal-title":"Arthritis Care & Research"},{"key":"2025121407493758000_15.6.e098298.26","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780390105"},{"key":"2025121407493758000_15.6.e098298.27","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2474-15-14","article-title":"Real-world effectiveness of abatacept for rheumatoid arthritis treatment in European and Canadian populations: a 6-month interim analysis of the 2-year, observational, prospective ACTION study","volume":"15","author":"N\u00fc\u00dflein","year":"2014","journal-title":"BMC Musculoskelet Disord"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2024-098298","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,14]],"date-time":"2025-12-14T15:49:45Z","timestamp":1765727385000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2024-098298"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":27,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,6,17]]},"published-print":{"date-parts":[[2025,6]]}},"alternative-id":["10.1136\/bmjopen-2024-098298"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2024-098298","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"type":"print","value":"2044-6055"},{"type":"electronic","value":"2044-6055"}],"subject":[],"published":{"date-parts":[[2025,6]]}}}